Le Lézard
Classified in: Science and technology, Covid-19 virus
Subject: Contract/Agreement

Biorasi Selects IBM Watson Health as Preferred Vendor


Biorasi, a leading global full-service contract research organization (CRO), announced today that they have selected IBM Watson Health (IBM) as a preferred vendor. This relationship with IBM Watson Health expands Biorasi's capabilities in clinical trial execution and management through IBM's Clinical Development (ICD) platform ? a clinical data management system (CDMS) designed to help bring efficiency and speed to the clinical trial process.

"The collaboration with IBM Watson Health spotlights our vital business relationship and the innovative capabilities of the ICD solution," said Roberto Silberwasser, Senior Director of Data Sciences and Biometrics at Biorasi. "IBM's technology solutions not only complement Biorasi's core competencies as a CRO, but those of other preferred vendors as well."

ICD is a single-instance, fully-integrated, SaaS clinical data management system (CDMS) designed to help reduce the cycle time to start, amend, and manage clinical studies. The platform enables clinical trial sponsors and clinical site staff to reduce time and cost for clinical trials by centralizing and organizing information and providing 24/7 access to data via a single URL from any web-enabled device. It also serves as a flexible and scalable data management platform to help design and manage clinical trials by incorporating optional clinical trial-specific features. In a previous clinical study, Biorasi was able to reduce database build time by 25 percent ? and overall project costs by more than half ? by leveraging ICD's capabilities.

"We are moving into a new era of clinical development as the COVID-19 crisis has reinforced the desperate need to find meaningful ways to help accelerate the clinical trial process," said Mary Varghese Presti, Vice President, Life Sciences, IBM Watson Health. "Biorasi has been at the forefront of e-clinical innovation and has demonstrated continued leadership in leveraging the ICD platform. We are proud to support Biorasi's ongoing effort to bring greater efficiency and precision to the clinical trial process, particularly in emerging areas such as digital therapeutics, virtual trials and rescue studies."

About Biorasi

Biorasi is a customer-focused, full-service, contract research organization (CRO) that leverages speed and agility in the execution of clinical trials to maximize speed-to-market for its sponsors ? all powered by our proprietary TALOStm project management system. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market. To learn more, contact Biorasi at [email protected] / (786) 388-0700.


These press releases may also interest you

at 17:05
Sky Harbour Group Corporation ("SHG" or the "Company"), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, today announced that it will release its First Quarter 2024 financial...

at 17:00
Victoria Gold Corp. ("Victoria" or the "Company") held its Annual General Meeting (the "Meeting") earlier today, May 10, 2024, in Vancouver, British Columbia. Shareholders voted in favour of all items proposed by the board of directors and...

at 17:00
Canada Jetlines Operations Ltd. (Cboe CA:CJET) ("Canada Jetlines" or the "Company"), one of Canada's leading leisure airlines, today reported financial results for the first quarter ended March 31, 2024. All financial figures are...

at 16:16
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...

at 16:05
Applied DNA Sciences, Inc. ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can...

at 14:41
Striking new work from the acclaimed visual artist behind the Covid flags on the Mall opened to the public today at Freedom Plaza in Washington, D.C. Suzanne Brennan Firstenberg launched her latest work "alienable right to life," at a moving opening...



News published on and distributed by: